Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 119

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

Testicular germ cell tumour

Recruiting

Study on Preventing Blood Clots in Patients with Advanced Germ Cell Tumors Using Cisplatin and a Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Cisplatin
  • Sponsor:Institut Gustave Roussy

HER2 positive breast cancer

Recruiting

Study Comparing Trastuzumab Deruxtecan with Standard Treatment for Patients with HER2-positive Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Karolinska University Hospital

Cholangiocarcinoma

Recruiting

Study on Ivosidenib for Patients with Previously Treated Advanced or Metastatic Cholangiocarcinoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Servier Affaires Medicales

Colorectal adenocarcinoma

Recruiting

Study of Pre-Operative Treatments with Sotorasib and Drug Combination for Patients with Resectable Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Fondazione GONO G.I.

Glioblastoma

Recruiting

Study of Debio 0123 and Temozolomide for Adults with Recurrent or Newly Diagnosed Glioblastoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sulfamethoxazole
  • Sponsor:Debiopharm International SA

Acute myeloid leukaemia (in remission)

Recruiting

Study Comparing Clofarabine/Busulfan and Fludarabine/Busulfan for Adults with Acute Myeloid Leukemia Eligible for Stem Cell Transplantation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Brain neoplasm

Recruiting

Study on Lithium Sulphate to Prevent Cognitive Impairment in Children After Brain Tumor Radiotherapy

Registered drug
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Lithium Sulphate, Anhydrous
  • Sponsor:Karolinska University Hospital

Non-small cell lung cancer stage IV

Recruiting

Study on the Effectiveness of Pembrolizumab with Chemotherapy in Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Levels

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Prostate cancer

Recruiting

Study Comparing 177Lu-PSMA-I&T with Apalutamide, Enzalutamide, and Abiraterone for Patients with Metastatic Hormone-Sensitive Prostate Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Region Vaesterbotten

Acute myeloid leukaemia

Recruiting

Study of Venetoclax and Decitabine for Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Decitabine
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Endometrial cancer

Recruiting

Study on Durvalumab for Patients with High-Risk Endometrial Cancer After Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Leiden University Medical Center

Neuroblastoma

Recruiting

Study of Lutetium (177Lu) Oxodotreotide for Children with Relapsed or Refractory High-Risk Neuroblastoma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Edotreotide
  • Sponsor:Karolinska University Hospital

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab467 clinical trialsCarboplatin344 clinical trialsCisplatin288 clinical trialsPaclitaxel266 clinical trialsFluorouracil239 clinical trialsOxaliplatin230 clinical trialsNivolumab218 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.